#122

Dayspring mentions here that both types of statin get into the brain eventually, so it doesn’t matter which one uses. I stopped Atorvastatin but I’m probably going to be starting a baby dose of Rosuvastatin again following your advice as Dayspring also mentions “baby statins” in this clip and it looks like Rosuvustatin is the most bang for buck in small doses.

I just “liked and subscribed” to your youtube channel btw. Look forward to seeing more.

1 Like
#123

Yes I’ve seen that episode with Dayspring. He’s almost certainly wrong on this. Atorvastatin (lipophilic) does get into the brain readily, whereas rosuvastatin (hydrophilic), if it gets in will be a much smaller amount.

Thanks for supporting the channel - and I’ll have better quality and detailed materials upcoming.

Vera-Health.ai says on this:
Rosuvastatin’s ability to cross the blood-brain barrier (BBB) is a topic of interest due to its potential implications for treating neurological conditions. The BBB is a selective barrier that regulates the passage of substances from the bloodstream into the central nervous system (CNS) 6.

A study by Sierra et al. compared various statins, including rosuvastatin, for their potential to penetrate the BBB and their neuroprotective effects. The study found that rosuvastatin has a lower potential for BBB penetration compared to more lipophilic statins like simvastatin 1. This is consistent with the general understanding that lipophilicity is a key factor in a drug’s ability to cross the BBB.

However, another study suggests that rosuvastatin may still have therapeutic potential in the CNS. It was shown to mitigate BBB disruption in sepsis-associated encephalopathy by restoring occludin levels, a tight junction protein critical for BBB integrity 2. This indicates that while rosuvastatin may not readily cross the BBB, it can influence BBB function and integrity.

Additionally, the role of transporters like organic anion transporting polypeptide 1a4 (Oatp1a4) at the BBB is crucial for the CNS disposition of statins. The regulation of these transporters by signaling pathways, such as the TGF-β/ALK1 pathway, can affect the distribution of statins like rosuvastatin in different brain regions 3.

In summary, while rosuvastatin may not have high BBB penetration due to its lower lipophilicity, it can still impact BBB function and potentially exert effects on the CNS through mechanisms involving BBB integrity and transporter regulation. This makes it a candidate for further research in neurological applications, despite its limited direct penetration into the brain. (ASHP Drug Compendium [Rosuvastatin; Statins

4 Likes
#124

I wonder what evidence Thomas Dayspring uses!
I think I looked at this previously and that he actually was correct that rosuvastatin also crosses the BBB.